Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 2,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Recruiting Not applicable Interventional

Adaptive and Individualized AAC Phase II

NCT06337188
View directory record Official record
Conditions
Communication Disorders
Interventions
Experimental AAC, Generic AAC
Device
Lead sponsor
Altec Inc.
Industry
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 4, 2026, 7:59 AM EST
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Leukoplakia of the Mouth

NCT00004161
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
fenretinide, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Nov 4, 2026, 7:59 AM EST
Terminated Phase 2 Interventional

A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

NCT05803551
View directory record Official record
Conditions
Depression
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)

NCT01221129
View directory record Official record
Conditions
Zinc Deficiency
Interventions
Acclimation, Dietary zinc depletion, Dietary zinc repletion
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Nov 4, 2026, 7:59 AM EST
Suspended Phase 3 Interventional

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00324831
View directory record Official record
Conditions
Lymphoma
Interventions
autologous immunoglobulin idiotype-KLH conjugate vaccine, cyclophosphamide, doxorubicin hydrochloride, prednisone, rituximab, sargramostim, vincristine, Intervention/procedure, antibody therapy, biological therapy, chemotherapy, colony-stimulating factor therapy, cytokine therapy, monoclonal antibody therapy, non-specific immune-modulator therapy, therapeutic procedure, tumor cell derivative vaccine, vaccine therapy
Drug · Procedure
Lead sponsor
Favrille
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Beverly Hills, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Nov 4, 2026, 7:59 AM EST
Not listed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

NCT04497805
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-SHEET
Biological
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Nov 4, 2026, 7:59 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Intra-operative Imaging in Women With Ovarian Cancer

NCT04878094
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma
Interventions
Intravenous Indocyanine Green/ICG injection, PINPOINT endoscopic fluorescence imaging system, Endoscopy
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Study of Food Aversion in Patients With Anorexia Nervosa

NCT03100656
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
A breakfast sandwich
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Eating, Activity, & Lifestyle Training Headquarters: II Pilot Project

NCT02905422
View directory record Official record
Conditions
Overweight, Weight Loss
Interventions
H.E.A.L.T.H. II Intervention
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Nov 4, 2026, 7:59 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)

NCT03354143
View directory record Official record
Conditions
Hypertension
Interventions
Standard Care, Intensive Treatment
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years to 79 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Nov 4, 2026, 7:59 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

NCT06655896
View directory record Official record
Conditions
Scleroderma, Diffuse
Interventions
rapcabtagene autoleucel, rituximab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • San Pablo, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer

NCT03032250
View directory record Official record
Conditions
Caregiver, Malignant Head and Neck Neoplasm, Paranasal Sinus Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage I Hypopharyngeal Squamous Cell Carcinoma, Stage I Laryngeal Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Squamous Cell Carcinoma, Stage II Laryngeal Squamous Cell Carcinoma, Stage II Lip and Oral Cavity Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Squamous Cell Carcinoma, Stage III Lip and Oral Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Squamous Cell Carcinoma, Stage IV Lip and Oral Cavity Squamous Cell Carcinoma, Stage IV Oropharyngeal Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal SCC, Recurrent Paranasal Sinus Squamous Cell Carcinoma
Interventions
Communication Intervention, Watch video, Module completion of the Prepare to Care kit, Quality-of-Life Assessment, Survey Administration, Salivary cortisol collection
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Nov 4, 2026, 7:59 AM EST
Completed Not applicable Interventional

Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study

NCT03775759
View directory record Official record
Conditions
Tricuspid Valve Insufficiency, Right Heart Failure, Heart Failure
Interventions
Tricuspid valve repair or replacement, Medical management of tricuspid regurgitation
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Nov 4, 2026, 7:59 AM EST
Completed Phase 2 Interventional Results available

Modafinil and Naltrexone to Reduce Cocaine and Alcohol Dependence

NCT00142818
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcoholism, Cocaine-Related Disorders
Interventions
Naltrexone, Modafinil, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Nov 4, 2026, 7:59 AM EST
Terminated Phase 2 Interventional

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NCT02728388
View directory record Official record
Conditions
NEUROFIBROMATOSIS 1
Interventions
aminolevulinic acid
Drug
Lead sponsor
Donald Basel
Other
Eligibility
14 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Completed Phase 2 Interventional Results available

Development of an Ergonomic Wheelchair Pushrim

NCT00392860
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Natural-Fit, PalmRim, Handrim Control Group
Device
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2014 · Synced Nov 4, 2026, 7:59 AM EST
Terminated Not applicable Interventional Results available

Arthrex Eclipse™ Shoulder Prosthesis

NCT01790113
View directory record Official record
Conditions
Osteoarthritis
Interventions
Univers™, Eclipse™ Total Shoulder Replacement
Device
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
21 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
16
States / cities
Sun City, Arizona • Redwood City, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 4, 2026, 7:59 AM EST
Not listed Phase 2 Interventional

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Duloxetine 60 mg qd, Lorcaserin
Drug
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Nov 4, 2026, 7:59 AM EST
Completed Not applicable Interventional

Ashwagandha for Nighttime Waking

NCT07151261
View directory record Official record
Conditions
Disturbed Sleep
Interventions
Ashwagandha, Placebo
Dietary Supplement · Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 4, 2026, 7:59 AM EST
Terminated Phase 2 Interventional Results available

Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen

NCT04839965
View directory record Official record
Conditions
COVID-19
Interventions
Ampion, Saline
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Nov 4, 2026, 7:59 AM EST
Completed Phase 2 Interventional Results available

Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis

NCT03782792
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 4, 2026, 7:59 AM EST
Completed Phase 1Phase 2 Interventional Results available

COVID-19 Study of Safety and Tolerability of Alvelestat

NCT04539795
View directory record Official record
Conditions
Covid19
Interventions
Alvelestat, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Nov 4, 2026, 7:59 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Patient-Reported Outcome Version of the Common Criteria for Adverse Events

NCT04050072
View directory record Official record
Conditions
Survivorship, Cancer
Interventions
Childhood Cancer Survivors (CCSS), SJLIFE, Community non-cancer control
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
16 Years and older
Enrollment
837 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 4, 2026, 7:59 AM EST